Cutter & Co Brokerage’s BioLineRX BLRX Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2024
Q4 | – | Sell |
-417
| Closed | -$9K | – | 212 |
|
|
2024
Q3 | $9K | Hold |
417
| – | – | ﹤0.01% | 215 |
|
|
2024
Q2 | $9.5K | Hold |
417
| – | – | ﹤0.01% | 205 |
|
|
2024
Q1 | $18.7K | Hold |
417
| – | – | ﹤0.01% | 206 |
|
|
2023
Q4 | $26.2K | Hold |
417
| – | – | 0.01% | 193 |
|
|
2023
Q3 | $30.3K | Hold |
417
| – | – | 0.01% | 202 |
|
|
2023
Q2 | $26.7K | Hold |
417
| – | – | 0.01% | 208 |
|
|
2023
Q1 | $14.8K | Hold |
417
| – | – | ﹤0.01% | 215 |
|
|
2022
Q4 | $9.83K | Sell |
417
-50
| -11% | -$1.49K | ﹤0.01% | 215 |
|
|
2022
Q3 | $17K | Hold |
467
| – | – | 0.01% | 221 |
|
|
2022
Q2 | $24K | Hold |
467
| – | – | 0.01% | 225 |
|
|
2022
Q1 | $32K | Hold |
467
| – | – | 0.01% | 226 |
|
|
2021
Q4 | $38K | Hold |
467
| – | – | 0.01% | 271 |
|
|
2021
Q3 | $51K | Hold |
467
| – | – | 0.01% | 292 |
|
|
2021
Q2 | $52K | Sell |
467
-250
| -35% | -$29.4K | 0.01% | 298 |
|
|
2021
Q1 | $80K | Hold |
717
| – | – | 0.02% | 282 |
|
|
2020
Q4 | $72K | Sell |
717
-8
| -1% | -$699 | 0.02% | 264 |
|
|
2020
Q3 | $48K | Buy |
725
+280
| +63% | +$21.2K | 0.01% | 252 |
|
|
2020
Q2 | $30K | Buy |
445
+100
| +29% | +$6.83K | 0.01% | 232 |
|
|
2020
Q1 | $18K | Buy |
345
+50
| +17% | +$3.96K | 0.01% | 223 |
|
|
2019
Q4 | $27K | Buy |
+295
| New | +$30.4K | 0.01% | 248 |
|
|
2019
Q3 | – | Sell |
-95
| Closed | -$21K | – | 301 |
|
|
2019
Q2 | $21K | Hold |
95
| – | – | 0.01% | 300 |
|
|
2019
Q1 | $25K | Buy |
95
+38
| +67% | +$11.1K | 0.01% | 290 |
|
|
2018
Q4 | $15K | Sell |
57
-3
| -5% | -$1.44K | 0.01% | 266 |
|
|
2018
Q3 | $39K | Hold |
60
| – | – | 0.01% | 279 |
|
|
2018
Q2 | $32K | Hold |
60
| – | – | 0.01% | 243 |
|
|
2018
Q1 | $31K | Hold |
60
| – | – | 0.01% | 249 |
|
|
2017
Q4 | $39K | Buy |
60
+8
| +15% | +$5.27K | 0.02% | 251 |
|
|
2017
Q3 | $35K | Hold |
52
| – | – | 0.01% | 258 |
|
|
2017
Q2 | $26K | Hold |
52
| – | – | 0.01% | 271 |
|
|
2017
Q1 | $30K | Buy |
52
+10
| +24% | +$6.44K | 0.01% | 260 |
|
|
2016
Q4 | $23K | Buy |
42
+4
| +11% | +$2.48K | 0.01% | 248 |
|
|
2016
Q3 | $26K | Sell |
38
-4
| -10% | -$2.13K | 0.01% | 244 |
|
|
2016
Q2 | $20K | Buy |
+42
| New | +$23.5K | 0.01% | 241 |
|
|
2015
Q4 | – | Sell |
-21
| Closed | -$19K | – | 221 |
|
|
2015
Q3 | $19K | Hold |
21
| – | – | 0.01% | 213 |
|
|
2015
Q2 | $33K | Sell |
21
-4
| -16% | -$4.95K | 0.01% | 247 |
|
|
2015
Q1 | $32K | Buy |
25
+8
| +47% | +$9.85K | 0.01% | 223 |
|
|
2014
Q4 | $16K | Buy |
+17
| New | +$14.8K | 0.01% | 252 |
|
Other funds holding BLRX
HCM
VFA
AWS
OGF
GI
Cutter & Co Brokerage's BLRX Position: Q4 2024 in Review
Cutter & Co Brokerage sold out of BioLineRX (BLRX) in Q4 2024, closing a stake of 417 shares — an estimated $9K sold.
Cutter & Co Brokerage first reported a position in BLRX in Q4 2014 and held it in 37 quarters. The position peaked at $80K in Q1 2021. 31 funds tracked by Wall St. Rank hold BLRX as of Q4 2024.
- Cutter & Co Brokerage reported no remaining BioLineRX position as of Q4 2024 after selling out during the quarter.
- Cutter & Co Brokerage sold 417 BioLineRX shares in Q4 2024, an estimated $9K.
- Cutter & Co Brokerage first reported a position in BioLineRX in Q4 2014 and held it in 37 quarters.
- Cutter & Co Brokerage's BioLineRX position peaked at $80K in Q1 2021.
- 31 funds tracked by Wall St. Rank held BioLineRX as of Q4 2024.
Based on Cutter & Co Brokerage's 13F filing for Q4 2024, filed 4 Feb 2025.